{"product_id":"mallinckrodt-business-model-canvas","title":"Mallinckrodt Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMallinckrodt's Business Model: A Strategic Deep Dive\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Mallinckrodt's business model. This in-depth Business Model Canvas reveals how the company drives value, captures market share, and stays ahead in a competitive landscape.\u003c\/p\u003e\n\u003cp\u003eDive deeper into Mallinckrodt’s real-world strategy with the complete Business Model Canvas. From value propositions to cost structure, this downloadable file offers a clear, professionally written snapshot of what makes this company thrive—and where its opportunities lie.\u003c\/p\u003e\n\u003cp\u003eWant to see exactly how Mallinckrodt operates and scales its business? Our full Business Model Canvas provides a detailed, section-by-section breakdown, perfect for benchmarking or strategic planning.\u003c\/p\u003e\n\u003cp\u003eGain exclusive access to the complete Business Model Canvas used to map out Mallinckrodt’s success. This professional, ready-to-use document is ideal for learning from proven industry strategies.\u003c\/p\u003e\n\u003cp\u003eSee how the pieces fit together in Mallinckrodt’s business model. This detailed, editable canvas highlights the company’s customer segments, key partnerships, revenue strategies, and more. Download the full version to accelerate your own business thinking.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch Institutions \u0026amp; Academia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMallinckrodt's partnerships with research institutions and academia are vital for its innovation in niche areas like autoimmune and rare diseases. Collaborating with universities provides access to early-stage scientific discoveries and novel therapeutic targets, bolstering their pipeline. For instance, in 2024, such collaborations continue to be crucial as Mallinckrodt focuses on developing therapies for conditions like Hypophosphatasia and Atopic Dermatitis. This strategy allows the company to build its portfolio of specialty pharmaceuticals from foundational research, leveraging external expertise for drug development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Research Organizations (CROs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eContract Research Organizations (CROs) are crucial for Mallinckrodt, handling the complex and costly execution of clinical trials. By outsourcing trial management, patient recruitment, and data analysis, Mallinckrodt operates with greater efficiency and flexibility, especially given the global CRO market size was projected to exceed 80 billion USD in 2024. This partnership model enables them to simultaneously run multiple trials across diverse geographies and therapeutic areas, optimizing resource allocation. Such collaborations are vital for accelerating drug development pipelines, allowing Mallinckrodt to focus on core R\u0026amp;D and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers \u0026amp; Hospital Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealthcare providers and hospital systems are essential partners for Mallinckrodt, extending beyond a mere customer relationship. These collaborations are crucial for the proper delivery and administration of therapies, especially critical care products used in neonatal intensive care units and specialized treatments for rare diseases. For example, in 2024, the continued engagement with major hospital networks ensures effective patient access to vital medications like Acthar Gel. These deep-rooted relationships are also indispensable for gathering real-world evidence, which supports product efficacy and safety, and ensures optimal product usage in complex clinical settings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Wholesalers \u0026amp; Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMallinckrodt relies heavily on pharmaceutical wholesalers and distributors, which serve as the logistical backbone for product delivery. These partners, including major players like McKesson, AmerisourceBergen, and Cardinal Health, manage the intricate warehousing, transportation, and final mile delivery of medications. They ensure Mallinckrodt’s critical products reach pharmacies, hospitals, and specialty clinics efficiently across the United States. A robust distribution network is essential for maintaining supply chain reliability, especially for life-saving medications, ensuring continuity of patient care in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eMajor distributors handle over 90% of pharmaceutical product flow in the US.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eStrategic partnerships reduce Mallinckrodt's operational logistics costs.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eReliable distribution is vital post-bankruptcy for market re-establishment.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eEnsures broad market access for diverse product portfolio.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Clients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs a contract manufacturer, Mallinckrodt forms essential partnerships with other pharmaceutical companies. These clients leverage Mallinckrodt's specialized manufacturing expertise and extensive infrastructure to produce their proprietary products. This symbiotic relationship diversifies Mallinckrodt's revenue streams, complementing its core branded drug portfolio. Such collaborations enhance operational utilization and provide consistent income, crucial for financial stability in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eClients rely on Mallinckrodt's cGMP facilities.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThese partnerships contribute to consistent asset utilization.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe revenue stream helps offset market volatility.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eDiversification supports long-term operational resilience.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances: Powering Pharma's 2024 Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMallinckrodt's strategic alliances with research institutions, CROs, and healthcare providers are fundamental for drug discovery, clinical development, and patient access. Partnerships with major pharmaceutical wholesalers ensure efficient product distribution, vital for their 2024 market presence. As a contract manufacturer, Mallinckrodt also collaborates with other pharma companies, diversifying revenue streams.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartnership Type\u003c\/th\u003e\n\u003cth\u003eStrategic Benefit\u003c\/th\u003e\n\u003cth\u003e2024 Impact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Academia\u003c\/td\u003e\n\u003ctd\u003eInnovation Access\u003c\/td\u003e\n\u003ctd\u003ePipeline advancement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\u003c\/td\u003e\n\u003ctd\u003eClinical Efficiency\u003c\/td\u003e\n\u003ctd\u003eAccelerated trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003eMarket Reach\u003c\/td\u003e\n\u003ctd\u003eReliable product delivery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA meticulously crafted business model canvas detailing Mallinckrodt's strategy, covering customer segments, value propositions, and revenue streams.\u003c\/p\u003e\n\u003cp\u003eThis canvas offers a clear, insightful overview of Mallinckrodt's operational framework, ideal for strategic analysis and stakeholder communication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThe Mallinckrodt Business Model Canvas offers a structured approach to quickly identify and address critical business challenges.\u003c\/p\u003e\n\u003cp\u003eIt acts as a pain point reliever by providing a clear, actionable framework for strategic problem-solving.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch \u0026amp; Development (R\u0026amp;D)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResearch and Development is a core activity for Mallinckrodt, driving its future growth by discovering and developing novel therapies, particularly in areas like autoimmune and rare diseases. This involves substantial investment in preclinical studies and clinical trials, with the company historically focusing on pipeline expansion. For instance, pharmaceutical R\u0026amp;D spending globally was projected to exceed $280 billion in 2024, highlighting the industry's commitment. Successful R\u0026amp;D is critical for bringing high-value specialty products to market, securing long-term revenue streams for pharmaceutical companies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmaceutical Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOperating state-of-the-art, compliant manufacturing facilities is a central activity for Mallinckrodt to produce its complex specialty and critical care drugs.\u003c\/p\u003e\n\u003cp\u003eThe company rigorously adheres to Good Manufacturing Practices (GMP) across its global sites, ensuring product quality and safety.\u003c\/p\u003e\n\u003cp\u003eThis commitment supports a consistent supply for patients, crucial for its portfolio that contributed to the company’s focus on specialty products in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs \u0026amp; Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNavigating the complex global regulatory landscape is a critical activity for Mallinckrodt, especially after emerging from Chapter 11 bankruptcy in April 2024.\u003c\/p\u003e\n\u003cp\u003eThis involves preparing and submitting extensive documentation to health authorities like the FDA and EMA for product approvals and lifecycle management. For example, maintaining compliance for drugs like Acthar Gel, which generated approximately $1.1 billion in net sales in fiscal year 2023, requires continuous regulatory vigilance.\u003c\/p\u003e\n\u003cp\u003eOngoing compliance with all evolving regulatory requirements, including post-marketing surveillance and labeling updates, is essential to keep products on the market and avoid significant penalties.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing \u0026amp; Sales to Specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMallinckrodt focuses highly targeted marketing and sales efforts on medical specialists, including neurologists, rheumatologists, and neonatologists, crucial for their niche pharmaceutical portfolio. This involves educating healthcare professionals on the clinical benefits and proper use of therapies like Acthar Gel, which generated $199 million in net sales for the three months ended March 29, 2024. This specialized approach is essential for driving adoption and ensuring appropriate utilization of their unique products within specific disease areas.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eMallinckrodt’s 2024 Q1 net sales for Acthar Gel were $199 million.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSpecialized sales teams engage key opinion leaders in neurology and rheumatology.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eEducational programs highlight clinical evidence and patient outcomes.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eTargeted marketing minimizes broader outreach, focusing on high-value prescribers.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Development \u0026amp; Manufacturing (CDMO) Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMallinckrodt leverages its robust manufacturing assets and deep pharmaceutical expertise to offer Contract Development \u0026amp; Manufacturing Organization (CDMO) services to other drug companies. This crucial activity spans process development, scaling up production, and commercial manufacturing for third-party clients, effectively utilizing existing operational capacity to generate additional revenue. As of early 2024, the global CDMO market continues its growth, benefiting companies like Mallinckrodt that possess specialized capabilities.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eMallinckrodt’s CDMO segment utilizes its advanced facilities, including capabilities for controlled substances.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThis service diversifies revenue streams beyond proprietary drug sales.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe global pharmaceutical CDMO market size was projected to reach over $200 billion by 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eIncreased outsourcing by pharmaceutical companies drives demand for CDMO services.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDriving Specialty Drug Innovation \u0026amp; Production\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMallinckrodt’s core activities encompass extensive Research and Development for novel therapies and operating compliant manufacturing facilities for its specialty drugs. They meticulously navigate complex global regulatory landscapes for product approvals and lifecycle management. Furthermore, the company engages in highly targeted marketing and sales to medical specialists, alongside offering Contract Development \u0026amp; Manufacturing Organization services, leveraging its specialized capabilities.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eFocus\u003c\/th\u003e\n\u003cth\u003e2024 Data\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eNovel Therapies\u003c\/td\u003e\n\u003ctd\u003eGlobal R\u0026amp;D \u0026gt; $280B projected\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eSpecialty Drug Production\u003c\/td\u003e\n\u003ctd\u003eEnsures consistent supply for 2024 portfolio\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketing \u0026amp; Sales\u003c\/td\u003e\n\u003ctd\u003eTargeted to Specialists\u003c\/td\u003e\n\u003ctd\u003eActhar Gel Q1 2024 sales: $199M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO Services\u003c\/td\u003e\n\u003ctd\u003eThird-Party Manufacturing\u003c\/td\u003e\n\u003ctd\u003eGlobal CDMO market \u0026gt; $200B projected\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Mallinckrodt Business Model Canvas preview you are viewing is the authentic document that will be delivered to you upon purchase. This means you are seeing the actual structure, content, and formatting that you will receive, ensuring complete transparency. Once your order is processed, you will gain full access to this exact same comprehensive Business Model Canvas, ready for your immediate use and customization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55480450351481,"sku":"mallinckrodt-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/mallinckrodt-business-model-canvas.png?v=1752753919","url":"https:\/\/growthsharematrix.com\/products\/mallinckrodt-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}